Tolerogenic insulin peptide therapy precipitates type 1 diabetes

• Author(s): Bergman, Marie-Louise ; Lopes-Carvalho, Thiago ; Martins, Ana-Catarina ; Grieco, Fabio A. ; Eizirik, Décio L. ; Demengeot, Jocelyne
• Date: 2017
• Persistent ID: http://hdl.handle.net/10400.7/820
• Origin: ARCA - Access to Research and Communication Annals
• Subject(s): Animals; Autoantibodies; Diabetes Mellitus, Type 1; Female; Hyperglycemia; Insulin; Insulin Antibodies; Mice, Inbred NOD; Microscopy, Fluorescence; Vaccination; Epitopes; Autoimmunity
• Document Type: Journal article
• Language: Portuguese
• Contributor(s): ARCA

Description

Daniel et al. (https://doi.org/10.1084/jem.20110574) have previously published in JEM a study on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Our study now challenges these results and shows that osmotic pump delivery of the modified insulin peptide R22E did not prevent hyperglycemia, accelerated disease onset, increased its incidence, and worsened insulitis.